Eli Lilly and Co (LLY)
745.69
+14.36
(+1.96%)
USD |
NYSE |
Apr 23, 16:00
747.52
+1.83
(+0.25%)
Pre-Market: 08:46
Eli Lilly Cash from Financing (TTM): 3.496B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.496B |
| September 30, 2023 | -1.190B |
| June 30, 2023 | -3.026B |
| March 31, 2023 | -2.116B |
| December 31, 2022 | -5.407B |
| September 30, 2022 | -5.792B |
| June 30, 2022 | -4.992B |
| March 31, 2022 | -5.951B |
| December 31, 2021 | -4.131B |
| September 30, 2021 | -3.896B |
| June 30, 2021 | -3.712B |
| March 31, 2021 | -4.302B |
| December 31, 2020 | -3.137B |
| September 30, 2020 | -2.959B |
| June 30, 2020 | -4.373B |
| March 31, 2020 | -3.586B |
| December 31, 2019 | -2.324B |
| September 30, 2019 | -2.851B |
| June 30, 2019 | -725.00M |
| March 31, 2019 | -670.60M |
| December 31, 2018 | -5.905B |
| September 30, 2018 | -4.808B |
| June 30, 2018 | -4.740B |
| March 31, 2018 | -2.848B |
| December 31, 2017 | 142.60M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.070B |
| June 30, 2017 | -30.70M |
| March 31, 2017 | -511.30M |
| December 31, 2016 | -559.80M |
| September 30, 2016 | -1.816B |
| June 30, 2016 | -1.812B |
| March 31, 2016 | -3.334B |
| December 31, 2015 | -3.111B |
| September 30, 2015 | -702.50M |
| June 30, 2015 | -513.20M |
| March 31, 2015 | -272.50M |
| December 31, 2014 | -166.40M |
| September 30, 2014 | -2.740B |
| June 30, 2014 | -2.863B |
| March 31, 2014 | -2.694B |
| December 31, 2013 | -3.829B |
| September 30, 2013 | -4.058B |
| June 30, 2013 | -4.074B |
| March 31, 2013 | -4.093B |
| December 31, 2012 | -4.420B |
| September 30, 2012 | -3.805B |
| June 30, 2012 | -3.702B |
| March 31, 2012 | -3.713B |
| December 31, 2011 | -2.370B |
| September 30, 2011 | -2.269B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-5.951B
Minimum
Mar 2022
3.496B
Maximum
Dec 2023
-3.209B
Average
-3.586B
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
| Amgen Inc | 21.05B |
| Biogen Inc | 149.30M |
| Madrigal Pharmaceuticals Inc | 595.12M |
| Vertex Pharmaceuticals Inc | -562.20M |
| Viking Therapeutics Inc | 271.38M |